repinatrabit (JNT-517) / Otsuka - LARVOL DELTA

A Study to Evaluate the Long-Term Safety and Efficacy of JNT-517 in Participants With Phenylketonuria (clinicaltrials.gov) - P3 | N=45 | Not yet recruiting | Sponsor: Jnana Therapeutics | Initiation date: Nov 2024 ➔ Jun 2025

Trial initiation date • Metabolic Disorders • Phenylketonuria • Rare Diseases

A Study to Evaluate the Safety and Efficacy of JNT-517 in Participants With Phenylketonuria (PKU) (clinicaltrials.gov) - P3 | N=120 | Not yet recruiting | Sponsor: Jnana Therapeutics

New P3 trial • Metabolic Disorders • Phenylketonuria • Rare Diseases

A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria (clinicaltrials.gov) - P2 | N=10 | Not yet recruiting | Sponsor: Jnana Therapeutics | Trial completion date: Sep 2025 ➔ Feb 2026 | Initiation date: Nov 2024 ➔ Jul 2025 | Trial primary completion date: Jul 2025 ➔ Dec 2025

Trial completion date • Trial initiation date • Trial primary completion date • Metabolic Disorders • Phenylketonuria • Rare Diseases

GSC002874, a highly potent inhibitor of SLC6A19, for treatment of phenylketonuria (ENDO 2025) - "For the classic PKU cohort accounting for over 60 percent of cases, the only approved drug is pegvaliase; however, it is associated with inconvenient dosing and side effects...In an PAH pR408W PKU mouse model with its mouse SLC6A19 replaced by human orthologue, GSC002874 significant decreased phenylalanine level in plasma at lower dosage that of JNT-517...GSC002874 is under active IND-enabling studies and expected to enter clinic in early 2026.*. .*"

Genetic Disorders • Metabolic Disorders • Phenylketonuria • Rare Diseases • SLC6A19

SLC6A19 inhibition facilitates urinary neutral amino acid excretion and lowers plasma phenylalanine. (PubMed, JCI Insight) - P1 | "Secondary objectives included pharmacokinetic and pharmacodynamic studies.RESULTSInhibition of SLC6A19 increased the urinary excretion of Phe in a mouse model of PKU, thereby reducing plasma Phe levels. JNT-517, an investigational oral SLC6A19 inhibitor, was found to be safe and well tolerated and increased the urinary excretion of Phe in a phase 1 healthy volunteer study.CONCLUSIONSThese data indicate that pharmacological inhibition of SLC6A19 presents a promising approach to lower toxic elevated levels of amino acids found in PKU and related amino acid metabolism disorders by facilitating their renal elimination.TRIAL REGISTRATIONAustralian New Zealand Clinical Trials Registry (ANZCTR), ACTRN12622001222730.FUNDINGThe studies in this paper were funded by Jnana Therapeutics."

Journal • Metabolic Disorders • Phenylketonuria • Rare Diseases • SLC6A19

A Phase 2 Study of JNT-517 in Adolescent Participants with Phenylketonuria (clinicaltrials.gov) - P2 | N=10 | Not yet recruiting | Sponsor: Jnana Therapeutics

New P2 trial • Metabolic Disorders • Phenylketonuria • Rare Diseases

A Study to Evaluate the Long-Term Safety and Efficacy of JNT-517 in Participants with Phenylketonuria (clinicaltrials.gov) - P3 | N=45 | Not yet recruiting | Sponsor: Jnana Therapeutics

New P3 trial • Metabolic Disorders • Phenylketonuria • Rare Diseases

JNT-517, A FIRST-IN-CLASS SLC6A19 INHIBITOR, REDUCES PLASMA PHENYLALANINE LEVELS IN SUBJECTS WITH PHENYLKETONURIA IN A PHASE 1/2 STUDY (SSIEM 2024) - "Treatment with JNT-517 in individuals with PKU demonstrated rapid clinically meaningful reductions in plasma Phe and was safe and well-tolerated."

Clinical • P1/2 data • Metabolic Disorders • Phenylketonuria • Rare Diseases • SLC6A19

Where are we now: Update on JNT-517 clinical trials in PKU (SSIEM 2024) - "Sponsored by JNANA THERAPEUTICS"

Clinical

JNT-517, A FIRST-IN-CLASS SLC6A19 INHIBITOR, REDUCES PLASMA PHENYLALANINE LEVELS IN SUBJECTS WITH PHENYLKETONURIA IN A PHASE 1/2 STUDY (SSIEM 2024) - "Treatment with JNT-517 in individuals with PKU demonstrated rapid clinically meaningful reductions in plasma Phe and was safe and well-tolerated."

Clinical • P1/2 data • Metabolic Disorders • Phenylketonuria • Rare Diseases • SLC6A19

Harnessing SLC6A19 as a potential treatment approach for PKU and related amino acid disorders (SSIEM 2024) - "Next, clinical trial data will be shared on treatment with JNT-517, the selective small molecule inhibitor, in PKU adults. The last part addresses the unmet medical needs of PKU and other amino acid disorders and potential for SLC6A19 inhibition as a treatment approach."

SLC6A19

A Phase 1, Three-Part Open-Label Drug-Drug Interaction Study in Healthy participants to Determine the Effects of Itraconazole on the Pharmacokinetics of JNT-517 (Victim) and the Effects of JNT-517 (Perpetrator) on the Pharmacokinetics of Midazolam and Pravastatin (ANZCTR) - P1 | N=36 | Completed | Sponsor: CTI Clinical Trial and Consulting Services Australia Pty Ltd | Recruiting ➔ Completed

Trial completion • Metabolic Disorders • Phenylketonuria • Rare Diseases

A Phase 1, Three-Part Open-Label Drug-Drug Interaction Study in Healthy participants to Determine the Effects of Itraconazole on the Pharmacokinetics of JNT-517 (Victim) and the Effects of JNT-517 (Perpetrator) on the Pharmacokinetics of Midazolam and Pravastatin (ANZCTR) - P1 | N=36 | Recruiting | Sponsor: CTI Clinical Trial and Consulting Services Australia Pty Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Metabolic Disorders • Phenylketonuria • Rare Diseases

A Phase 1, Three-Part Open-Label Drug-Drug Interaction Study in Healthy participants to Determine the Effects of Itraconazole on the Pharmacokinetics of JNT-517 (Victim) and the Effects of JNT-517 (Perpetrator) on the Pharmacokinetics of Midazolam and Pravastatin (ANZCTR) - P1 | N=36 | Not yet recruiting | Sponsor: CTI Clinical Trial and Consulting Services Australia Pty Ltd

New P1 trial • Metabolic Disorders • Phenylketonuria • Rare Diseases

JNT-517, a first-in-class SLC6A19 inhibitor for the treatment of phenylketonuria, enhances urinary excretion of phenylalanine in healthy volunteers (SIMD 2024) - "SLC6A19 inhibition by JNT-517 provides a safe and effective way to increase the excretion of neutral amino acids, including Phe, and may provide a novel therapeutic approach for individuals with PKU. Clinical testing of JNT-517 in PKU patients is currently ongoing."

Clinical • Metabolic Disorders • Phenylketonuria • Rare Diseases • SLC6A19

First in human clinical study of a novel drug JNT-517 to assess its safety and tolerability in healthy volunteers (ANZCTR) - P1 | N=72 | Completed | Sponsor: CTI Clinical Trial and Consulting Services Australia Pty Ltd. | Active, not recruiting ➔ Completed

Trial completion • Metabolic Disorders • Phenylketonuria • Rare Diseases

First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria (clinicaltrials.gov) - P1 | N=112 | Recruiting | Sponsor: Jnana Therapeutics | Trial completion date: Mar 2024 ➔ Mar 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Trial completion date • Trial primary completion date • Metabolic Disorders • Phenylketonuria • Rare Diseases

First in human clinical study of a novel drug JNT-517 to assess its safety and tolerability, effects of food intake and to compare JNT-517 levels when taken as an oral suspension and tablet formulation. (ANZCTR) - P1 | N=12 | Completed | Sponsor: CTI Clinical Trial and Consulting Services Australia Pty Ltd. | Active, not recruiting ➔ Completed | Initiation date: Feb 2000 ➔ Feb 2023

Trial completion • Trial initiation date • Metabolic Disorders • Phenylketonuria • Rare Diseases

First in human clinical study of a novel drug JNT-517 to assess its safety and tolerability in healthy volunteers (ANZCTR) - P1 | N=72 | Active, not recruiting | Sponsor: CTI Clinical Trial and Consulting Services Australia Pty Ltd. | Initiation date: Oct 2000 ➔ Oct 2022

Trial initiation date • Metabolic Disorders • Phenylketonuria • Rare Diseases

Safety, Tolerability and Proof-Of-Mechanism in Healthy Volunteers for JNT-517, a First-In-Class SLC6A19 Inhibitor for the Treatment of Phenylketonuria (SSIEM 2023) - "JNT-517 is a safe and well-tolerated novel SLC6A19 inhibitor, which effectively increases the excretion of neutral amino acids including Phe in urine and warrants investigation as a potential therapeutic candidate for PKU."

Clinical • Metabolic Disorders • Phenylketonuria • Rare Diseases • SLC6A19

Discovery and characterization of JNT-517, an inhibitor of SLC6A19 for the treatment of phenylketonuria (ACS-Fall 2023) - "We describe the discovery effort using our RAPID (Reactive Affinity Probe Interaction Discovery) chemoproteomics platform which led to small molecules that inhibited SLC6A19 and demonstrated in vivo activity in the Pahenu2 model. This work led to the identification of JNT-517, a first-in-class clinical candidate for the treatment of PKU."

Metabolic Disorders • Phenylketonuria • Psychiatry • Rare Diseases • SLC6A19

First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria (clinicaltrials.gov) - P1 | N=112 | Recruiting | Sponsor: Jnana Therapeutics

New P1 trial • Metabolic Disorders • Phenylketonuria • Rare Diseases

Jnana Therapeutics Raises $107 Million to Advance Lead PKU Program and Progress Therapeutics Pipeline Discovered by the RAPID Platforma (PRNewswire) - "Jnana Therapeutics...announced the close of its $107 million Series C financing. The financing was led by Bain Capital Life Sciences with participation from existing investors including RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures and Pfizer Ventures....The proceeds from the funding will be used to progress the company's lead program in phenylketonuria (PKU), a rare genetic metabolic disease, through a clinical proof-of-concept (POC) study, and to advance additional wholly owned, potential first-in-class medicines in immune-mediated diseases and cancer."

Financing • Oncology